AUTHORS
Danielle C. Kirkey, MD, Melia Blankenfeld, BS2, Bruce Liu3, Guangyan Xiong4, Isabel Lira, BS5, Grace Hawkins6, Jack H. Peplinski, MSc7, Rhonda E. Ries, MA8, LaKeisha Perkins9, Alex Hastie10, Hongbing Zhang11, Concetta Quintarelli, PhD12, Marco Becilli, MD13, Katherine Tarlock I, MD14, Franco Locatelli, MD PhD15, Cheng Liu, PhD16, Soheil Meshinchi, MD, PhD17
AFFILIATIONS
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Eureka Therapeutics, Inc., Emeryville, California, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States
11 Eureka Therapeutics, Inc., Emeryville, California, United States
12 Bambino Gesù Pediatric Hospital, Roma, Italy
13 Bambino Gesù Pediatric Hospital, Roma, Italy
14 Seattle Children's Hospital, Seattle, Washington, United States
15 Bambino Gesù Pediatric Hospital, Roma, Italy
16 Eureka Therapeutics, Inc., Emeryville, California, United States
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States
ABSTRACT
Extramedullary leukemia remains a clinical challenge across hematologic malignancies. Despite the success of chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies, responses remain consistently inferior in patients with extramedullary disease (EMD), suggesting EMD is a distinct biological barrier to durable cellular immunotherapy. We hypothesized that incomplete trafficking and eradication of leukemia within extramedullary sites permits persistence of viable leukemic cells that survive therapy and, following therapeutic T-cell contraction, reseed the peripheral blood (PB), bone marrow (BM), and distant organs, driving systemic relapse. We therefore propose that EMD functions as a protected reservoir of refractory leukemia requiring complete eradication for durable disease control. To test this, we developed complementary EMD models of acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL) to define the natural history of EMD dissemination and compare the activity of Eureka Therapeutics' ARTEMIS chimeric γδ antibody-TCR (AbTCR) T cells compared to conventional CAR-T cells.
Localized EMD xenograft models of mesothelin (MSLN)+ AML and CD19+ B-ALL were established using ffluciferase patient-derived and cell line-derived leukemias for longitudinal assessment of local growth and systemic dissemination. MSLN-directed T cells were prioritized because MSLN expression is associated with increased risk for EMD in AML. Mice received antigen-matched 2nd generation CAR-T or ARTEMIS AbTCR T cells. Responses were evaluated by serial bioluminescence imaging (BLI), PB flow cytometry, tumor measurements, BM assessment, tissue biodistribution, and survival.
To determine whether EMD functions as a reservoir for systemic leukemia, we first characterized untreated disease progression. In the MSLN+ AML PDX model, localized EMD reproducibly disseminated from the primary lesion to the PB, followed by extensive BM, liver, and spleen involvement. At harvest, untreated and unmodified T-cell-treated mice exhibited 40–80% AML in the BM, demonstrating that a single localized EMD lesion is sufficient to generate widespread systemic leukemia. An independent CD19+ B-ALL model showed remarkably similar biology. Following establishment of localized Rs4;11 EMD, untreated and unmodified T-cell-treated mice developed circulating leukemia by week 5, followed by BM, liver, and spleen dissemination in all animals. Together, these complementary models demonstrate that isolated EMD serves as a protected reservoir capable of continuously reseeding systemic disease.
We next evaluated whether ARTEMIS AbTCR T cells could effectivity eliminate sites of EMD. In the CD19+ B-ALL model, ARTEMIS induced a 4-log reduction in BLI (p<0.01), an 83% reduction in tumor volume (p<0.01), expansion to ~30% of circulating leukocytes at Day 14 and complete prevention of detectable BM dissemination through day 60. Conventional CD19 CAR-T cells also induced tumor regression but showed delayed kinetics, higher residual tumor burden, and slower EMD clearance. Comparable superiority was observed in the MSLN+ AML model. ARTEMIS AbTCR T cells produced 4-log reductions in leukemia burden, complete regression of EMD lesions, and durable disease control, with all treated mice alive and disease-free beyond day 100, whereas untreated controls succumbed by day 49 (p<0.001). Despite extensive BM involvement in controls, no AML cells were detected in BM aspirates from ARTEMIS-treated mice, demonstrating eradication of both localized EMD and occult systemic leukemia. Although MSLN CAR-T cells also induced regression, ARTEMIS T cells produced substantially deeper (>2-log) and faster responses.
These findings support a new biologic model in which EMD is a protected reservoir of refractory leukemia capable of reseeding systemic disease. Analogous to measurable residual disease (MRD) within the BM, persistent EMD may independently drive leukemic progression despite apparent medullary clearance. Using complementary AML and B-ALL models, we demonstrate that isolated EMD is sufficient to generate widespread systemic leukemia and that complete elimination of EMD is necessary to prevent systemic dissemination and occult BM relapse. These results suggest durable cellular immunotherapy requires eradication of both medullary and extramedullary disease and support ARTEMIS AbTCR T-cell therapy as a strategy to overcome this fundamental barrier to leukemia immunotherapy.
DISCLOSURES
Danielle C. Kirkey, MD: No relevant conflicts of interest to declare.